Melanoma of the nervous system

Hr, Beresford

doi:10.1212/wnl.19.1.59

Cited by 42 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median survival of patients with stage IV malignant melanoma (distant metastasis) remained poor during the 1970s and 1980s, ranging from 2 to 8 months [8][9][10][11][12][13][14][15]. The pace of systemic disease often outstrips the pace of neurologic disease even when the cerebral spread is palliated with corticosteroid treatment and whole brain irradiation [10,[16][17][18]. Many patients with both cerebral and systemic metastases die of non-neurologic causes.…”

Section: Discussionmentioning

confidence: 99%

Response of intracranial melanoma metastases to stereotactic radiosurgery

Gieger

Ling

et al. 1997

Radiat. Oncol. Investig.

View full text Add to dashboard Cite

We analyzed our recent stereotactic radiosurgery (SRS) experience to determine the radiographic response of intracranial metastatic melanomas to SRS. Twelve patients with 21 intracranial melanoma metastases treated with SRS were evaluated. Fifteen (72%) metastases were hemispheric, 3 (14%) were cerebellar, and 3 (14%) were in the basal ganglion or thalamus. All lesions were 2.5 cm or less in maximum diameter. Eleven patients also had whole brain external beam radiotherapy. Mean SRS dosage was 1,800 cGy to the 85% isodose surface and median dose was 1,800 cGy to the 80% isodose surface (range 1,100–3,100 cGy at the 80–95% isodose surface). Overall, 12 (57%) lesions showed decrease or stabilization of tumor volume (i.e., local control), while 9 (43%) showed enlargement. Division of metastases into small (≤1.0 cm diameter) and large (>1.0 cm diameter) tumors showed that the small tumors were more likely to regress than the large tumors (chi‐square test; P < 0.03). Only 1 of 9 (11%) large lesions regressed as opposed to 7 of 12 (58%) small lesions regressed with SRS. We conclude that SRS is suited for small melanoma brain metastases, but lesions between 1.0 and 2.5 cm in diameter, while still generally considered appropriate for SRS, may not be as responsive to SRS at currently employed dosages. Radiat. Oncol. Invest. 5:72–80, 1997. © 1997 Wiley‐Liss, Inc.

show abstract

Section: Discussionmentioning

confidence: 99%

Response of intracranial melanoma metastases to stereotactic radiosurgery

Gieger

Ling

et al. 1997

Radiat. Oncol. Investig.

View full text Add to dashboard Cite

show abstract

“…MM is a relatively radioresistant tumor, but the combination of radiotherapy and corticosteroids can provide effective palliation. 44,45 Seventy-three percent of patients with central nervous system metastases of MM had a response to steroids, whereas only 42% showed any response to radiotherapy. 45 Survival without surgical resection was Ͻ2 months with whatever dose or fractionation scheme was used.…”

Section: Discussionmentioning

confidence: 99%

Leptomeningeal melanoma in childhood

Makin¹,

Eden²,

Lashford³

et al. 1999

Cancer

View full text Add to dashboard Cite

show abstract

“…In adults, despite the greater numbers of appropriate trials to evaluate, there is still little consensus on the best therapy for metastatic MM. MM is a relatively radioresistant tumor, but the combination of radiotherapy and corticosteroids can provide effective palliation 44, 45. Seventy‐three percent of patients with central nervous system metastases of MM had a response to steroids, whereas only 42% showed any response to radiotherapy 45.…”

Section: Discussionmentioning

confidence: 99%

Leptomeningeal melanoma in childhood

Makin

Eden

Lashford

et al. 1999

Cancer

View full text Add to dashboard Cite

BACKGROUND Malignant melanoma (MM) is one of the least common types of childhood cancer, accounting for less than 1% of all pediatric malignancies. Neurocutaneous melanosis (NCM) is a rare phakomatosis consisting of congenital abnormal pigmentation of the skin and meninges. The meningeal lesions are particularly prone to malignant change. METHODS The authors describe 5 patients with NCM and 1 with primary leptomeningeal melanoma (LMM) seen at 2 treatment centers in the north of England over a 13‐year period (1984–1997). RESULTS The clinical features, progress, radiological findings, and treatment of these patients are discussed. All six died within eight months of their diagnosis, illustrating the difficulties faced in treating patients with these conditions. The authors reviewed the published literature on NCM, concentrating on the various therapeutic strategies that have been tried. Very little consistency in approach was found. Malignant skin lesions in NCM may be less responsive than primary malignant melanoma, but the small number of patients with primary LMM or brain metastases of MM make comparisons with NCM difficult. The authors' own series illustrates well the piecemeal nature of therapy for patients with these rare conditions. CONCLUSIONS The rate of incidence of MM melanoma in the U.K. is increasing, and it will represent an increasing proportion of the pediatric oncologist's workload. A consistent approach to the therapy of patients with metastatic MM and NCM is needed if we are to have any hope of offering more than palliative therapy to these children in the future. Cancer 1999;86:878–86. © 1999 American Cancer Society.

show abstract

Melanoma of the nervous system

Cited by 42 publications

References 0 publications

Response of intracranial melanoma metastases to stereotactic radiosurgery

Response of intracranial melanoma metastases to stereotactic radiosurgery

Leptomeningeal melanoma in childhood

Leptomeningeal melanoma in childhood

Contact Info

Product

Resources

About